On June 20, 2025, Cyclacel Pharmaceuticals, Inc. entered into a Securities Purchase Agreement, raising $3,000,000 by selling 3,000,000 shares of Series F Convertible Preferred Stock at $1.00 per share, along with warrants to purchase additional common stock. This transaction will support general corporate purposes and requires stockholder approval for future conversions.